Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

ract in a process that ultimately results in the persistent inflammation underlying IBD. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the GI system.

"Current approaches to the treatment of Crohn's disease often result in serious side effects, especially following long-term use of these drugs," said Pirow Bekker, M.D., Ph.D., Senior Vice President, Medical and Clinical Affairs of ChemoCentryx. "These results suggest that Traficet-EN has the potential to keep Crohn's patients in remission without complications such as broad immunosuppression associated with current therapies."

"Data generated from these two studies are groundbreaking in nature and have the potential to revolutionize the way Crohn's disease and ulcerative colitis are treated," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "We are particularly pleased that we have for the first time definitively identified the CCR9 chemokine ligand in the large bowel which will broaden the scope of digestive tract disorders that Traficet-EN could potentially treat successfully."

Results for PROTECT-1 Maintenance Period of Study

Over the course of the Maintenance period, the remission rate in the Traficet-EN group remained between 47% and 50%, whereas the remission rate continued to decrease in the placebo group. At week 36, 47% of subjects in the Traficet-EN group were in remission compared to 31% in the placebo group (p=0.01). Furthermore, at week 36, 41% of patients in the Traficet-EN group were in corticosteroid-free remission compared to 28% in the placebo group (p=0.04).

Study Design for PROTECT-1 Trial

The randomized, placebo-controlled, double-blind clinical trial of 436 patients is comprised of three discrete periods which allows for evaluation of efficacy and safety of Traficet-EN in inducing a cl
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... MELBOURNE, Australia , July 11, 2014  Australian ... today announced that it has raised A$19.3 million via ... Europe , the U.S., ... and A$3 million from a share purchase plan (SPP) ... A$16.3 million will be made in two tranches. ...
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... -- Golden Meditech Holdings Limited ("Golden Meditech" or ... today announced that the Group has accumulated 754,791 ordinary shares ... CO.US) from the open market between December 2010 and March ... 39.5% of the issued share capital of CCBC. ...
... Mass., June 23, 2011 SeraCare Life Sciences, Inc. (NASDAQ: ... vital products and services to facilitate the discovery, development and ... of an unsolicited offer from MSMB Capital proposing to purchase ... share. It is anticipated that the SeraCare Board of Directors ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2SeraCare Acknowledges Receipt of Unsolicited Proposal from MSMB Capital 2
(Date:7/13/2014)... Anson County, NC (PRWEB) July 13, 2014 ... ceremony of its newest location, the Carolinas HealthCare System ... dollar facility replaces the aged Anson Community Hospital in ... location is approximately three miles from the previous facility. ... a single-story floorplan that includes an emergency room drop-off, ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, ... Additionally, the company’s chief executive officer has announced a new ... are offered at discounted prices, from 15 to 26 percent ... are in huge demand in the current market. We are ... have a lot of high quality products for sale. Many ...
(Date:7/13/2014)... 2014 Advanced boilers are preferred ... amount of fossil fuels, produce high-capacity power, emit ... increased global warming and climate change concerns, many ... harmful gas emissions and pollutants coming from fossilfuel-based ... the global advance boilers market., The global power ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... A new type of sensor for people with diabetes is ... saliva instead of blood, researchers report. Scientists at Brown ... it using artificial saliva. It uses light, metal and a ... "Everybody knows that diabetics have to prick their fingers ...
(Date:7/13/2014)... Trujillo Alto, Puerto Rico (PRWEB) July 13, 2014 ... that NBA Hall of Famer, Chris Mullin, will be ... Meeting on Saturday, July 26th in Puerto Rico. ... opportunities. Chris Mullin will participate in two exhibition basketball ... Max International, the ultimate supplier of health- and ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... may help diagnose heart disease, cancers, HIV and other ... clinical methods. The microsponges are an essential component of ... a new paper in the journal Small . ... Professor in Bioengineering and Chemistry, and his colleagues at ...
... the highest adolescent pregnancy and birth rate among developed countries ... pregnant do not have aspirations of going to college or ... researchers at Women & Infants Hospital of Rhode Island shows ... college and get a good job. Whether or not the ...
... Kathleen Doheny HealthDay Reporter , WEDNESDAY, Feb. 9 ... every day may be cutting down on calories, but they ... suggests. "In our study, we saw a significant increased ... regular soda," said Hannah Gardener, an epidemiologist at the University ...
... Louisville School of Medicine professors recently authored reference works ... use of radiation treatment for childhood cancers and the ... Edward C. Halperin, dean of the school, is co-author ... Dr. Kelly M. McMasters, chair of the Department of ...
... the number of brain injuries and deaths from crashes, appear ... spine injury, new research from Johns Hopkins suggests. "We ... riding a motorcycle can be detrimental during a motorcycle crash," ... professor of surgery at the Johns Hopkins University School of ...
... reliance on coastal waters for food, trade and tourism ... closely monitored to guarantee their future sustainability. ESA,s ... full advantage of the unique capabilities of the Medium ... With a resolution of 300 m, MERIS ...
Cached Medicine News:Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:Research: Pregnant teens want to go to college, need support 2Health News:Can Diet Soda Boost Your Stroke Risk? 2Health News:Can Diet Soda Boost Your Stroke Risk? 3Health News:New works by UofL professors provide latest oncology reference guides 2Health News:Motorcycle helmets reduce spine injuries after collisions 2Health News:ESA's sharp eyes on coastal waters 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: